Immunocore $297 million IPO
We advised the joint book-running managers and underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
CureVac $450 million public offering
We advised CureVac on the equity offering
Editas Medicine $231 million stock offering
We advised the joint book-running managers in connection with the equity offering
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…
Veritiv secondary offering
Davis Polk advised the underwriter in connection with an SEC-registered secondary offering of 1,400,000 shares of Veritiv Corporation’s common stock by UWW Holdings, LLC. The common…
Coloplast acquisition of Nine Continents Medical
Davis Polk advised Coloplast on its acquisition of Nine Continents Medical, an early stage company pioneering an implantable tibial nerve stimulation treatment for over-active bladder. The…
Aligos Therapeutics $150 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $150 million initial public offering of 10,000,000 shares of common stock of Aligos…
Beam Therapeutics $127 million offering
Davis Polk advised the joint book-running managers in connection with an SEC-registered offering of 5,750,000 common shares of Beam Therapeutics Inc. for total gross proceeds of $127…
Mission Produce $96 million IPO
Davis Polk advised the representatives of the several underwriters in connection with the $96 million initial public offering by Mission Produce, Inc. of 8,000,000 shares of its…
Humanigen stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,200,000 shares of common stock of…